International Isotopes Inc. posts third-quarter revenue of $3.28 million and net loss of $204,000
International Isotopes Inc. reported revenue from the sale of product of $3.3 million for the third quarter of 2025, a decrease of 16% compared to the same period in the previous year. For the nine months ended September 30, 2025, revenue from the sale of product was $10.2 million, an increase of 2% from the prior year. The company reported a net loss of $203,600 for the third quarter, compared to a net profit of $150,300 in the same period last year. For the first nine months of 2025, net loss was $477,100, an increase from a net loss of $237,200 in the same period last year. Non-GAAP EBITDA for the first nine months of 2025 was $15,000. In the Fluorine Products segment, there were no sales, and the company incurred $26,100 and $82,300 in expenses for the three and nine months ended September 30, 2025, respectively. The company received $30,000 and $60,000 in extension payments related to the Fluorine Products Asset Sale during the same periods and is awaiting regulatory consent to complete the asset sale, expected by March 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. International Isotopes Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL24670) on November 14, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.